Dr. Lal PathLabs Limited has successfully completed the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited on May 01, 2026, pursuant to the terms and conditions of the Share Purchase Agreement. The company had earlier intimated the exchanges regarding this acquisition on April 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Following the completion of the acquisition, Shahbazkers Diagnostic Centre Private Limited has now become a wholly owned subsidiary of Dr. Lal PathLabs Limited. The disclosure requirements under Regulation 30 of the Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, were duly intimated in the earlier communication dated April 30, 2026.

Acquisition Details

The intimation was signed by Vinay Gujral, Company Secretary & Compliance Officer of Dr. Lal PathLabs Limited, and submitted to both the National Stock Exchange of India Limited and BSE Limited for necessary record. The official communication was digitally signed on May 01, 2026 at 19:16:40 +05'30.

Dr. Lal PathLabs Limited announced its audited financial results for the quarter and year ended March 31, 2026, following the Board of Directors meeting held on April 30, 2026. The company reported mixed quarterly performance with revenue growth but profit decline in Q4FY26. For the full fiscal year, the company maintained strong performance with consolidated revenue from operations of INR 27,629 million and consolidated profit of INR 5,098 million, representing growth from the previous year.

Q4FY26 Performance Analysis

The company's Q4FY26 results showed contrasting trends with revenue growth but profit compression. Consolidated net profit declined to INR 1.30 billion compared to INR 1.55 billion in the same quarter last year. However, revenue demonstrated strong growth, reaching INR 7.00 billion versus INR 6.03 billion in Q4FY25. EBITDA performance showed improvement, rising to INR 1.87 billion from INR 1.69 billion year-on-year, though EBITDA margin compressed to 26.60% from 28.05% in the previous year.

Full Year Financial Performance

For the complete financial year FY26, Dr. Lal PathLabs delivered robust performance with consolidated revenue from operations reaching INR 27,629 million, representing growth from INR 24,614 million in the previous year. Consolidated profit for the year stood at INR 5,098 million with earnings per share (basic) of INR 30.24. The standalone results showed revenue from operations of INR 26,476 million for FY26, with profit increasing to INR 5,082 million compared to INR 4,973 million in the previous year.

Dividend and Strategic Initiatives

The Board of Directors recommended a final dividend of INR 4.00 per equity share for FY26, subject to shareholder approval at the Annual General Meeting. The record date for dividend payment has been fixed as June 26, 2026. Including the final dividend, the total dividend for FY26 amounts to INR 20.50 per equity share, comprising interim dividends paid during the year.

The Board approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for a cash consideration not exceeding INR 20 crores. The company also approved the incorporation of a wholly owned subsidiary in Dubai, United Arab Emirates, named Dr. Lal PathLabs FZCO, subject to necessary regulatory approvals.

Corporate Governance and Management

The Board re-appointed (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director for five years commencing from April 1, 2027, subject to shareholder approval. Mr. Rajit Mehta was re-appointed as Non-Executive Independent Director for five years from July 27, 2026. The company also designated Dr. Reena Nakra and Dr. Saloni Khera as Senior Management Personnel effective April 30, 2026. The 32nd Annual General Meeting has been convened on July 25, 2026, through video conferencing.

Regulatory Compliance and Disclosure

Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has made available the audio recording of its earnings conference call with investors and analysts for Q4 & FY26 held on April 30, 2026. The recording is accessible on the company's official website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result , ensuring transparency and compliance with regulatory disclosure requirements.

In compliance with Regulation 30 and 47 of SEBI regulations, the company published newspaper advertisements of its financial results for the quarter and year ended March 31, 2026, in Financial Express and Jansatta on May 01, 2026. The advertisements were duly filed with the National Stock Exchange of India Limited and BSE Limited as per regulatory requirements.